Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Leeds
With
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of rheumatoid arthritis (2010 ACR/EULAR RA classification criteria)
Symptom duration ≤12months
No previous disease modifying antirheumatic drug (DMARD) therapy
Active RA at baseline (defined as: DAS28 ≥ 3.2)
Active hand and/or wrist joint evaluable by US and MRI (with no planned surgery during the study period)
Patients without any contraindication to MRI
You may not be if
Patients unwilling or unable to receive MTX for the duration of the study.
Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter's syndrome, psoriatic arthritis, systemic lupus erythematosis, or any arthritis with onset prior to 16 years of age.
Suspicion of diagnosis of tuberculosis (TB): positive quantiferon +/abnormal chest x-ray, as per clinician judgement. Prior history of TB with confirmed full chemotherapy +/latent TB adequately treated may be included as per physician's discretion.
Intramuscular, oral or intraarticular (of non-target joint) corticosteroid within 28 days of the screening visit; intra-articular steroid of the chosen target joint within 12 weeks of screening.
Patients with serious infections within 3 month of enrolment (screening) or persistent infections.
Patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ).
Known positive serology for hepatitis B or C, or HIV
